Financial Performance - The company's revenue for Q3 2023 reached RMB 10.67 billion, a year-on-year increase of 0.30%[8] - Net profit attributable to shareholders was RMB 2.76 billion, reflecting a year-on-year increase of 0.77%[8] - The net profit excluding non-recurring gains and losses was RMB 2.95 billion, up 23.76% year-on-year[8] - The diluted earnings per share for Q3 2023 was RMB 0.94, a 16.05% increase year-on-year[9] - The company achieved a revenue of RMB 2,954,132.61 million in the first three quarters of 2023, representing a year-on-year growth of 4.0%[13] - Total operating revenue for the first three quarters of 2023 reached ¥29,541,326,133.58, an increase from ¥28,394,561,790.41 in the same period of 2022, representing a growth of approximately 4%[27] - Net profit for the first three quarters of 2023 was ¥8,148,647,084.33, up from ¥7,446,617,606.20 in 2022, reflecting an increase of approximately 9.4%[27] - Basic earnings per share for the first three quarters of 2023 was ¥2.75, compared to ¥2.52 in the previous year, representing an increase of about 9.1%[28] - The company reported a net profit of CNY 2,791,751,000 in Q3 2023, slightly up from CNY 2,770,959,000 in Q3 2022, indicating consistent profitability[34] Revenue Breakdown - Revenue from U.S. clients was RMB 19.4 billion, a 36% increase year-on-year after excluding specific commercial production projects[12] - Revenue from the top 20 global pharmaceutical companies reached RMB 11.82 billion, showing a strong growth of 43% year-on-year after excluding specific commercial production projects[12] - The chemical business generated revenue of RMB 212.4 billion, a 2.0% increase year-on-year, with a strong growth of 31.0% when excluding specific commercial production projects[14] - The testing business reported revenue of RMB 48.5 billion, up 16.2% year-on-year, with a gross margin of 38.6%, an increase of 1.8 percentage points[15] - The biology business achieved revenue of RMB 18.9 billion, a 6.5% increase year-on-year, with a gross margin of 42.8%[16] - The TIDES business revenue reached RMB 20.7 billion, reflecting a robust growth of 38.1% year-on-year, with a significant order backlog increase of 245%[14] - The cell and gene therapy CTDMO business generated revenue of RMB 10.3 billion, growing by 11.6%, although it reported a negative gross margin of -6.1%[16] - The domestic new drug development services segment saw a revenue decline of 26.9% to RMB 4.9 billion, despite an improved gross margin of 31.6%[17] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period increased by 33.82% to RMB 10.32 billion[11] - The company's total assets as of the end of Q3 2023 were RMB 71.76 billion, a 10.93% increase from the end of the previous year[9] - The company's total cash and cash equivalents at the end of Q3 2023 stood at CNY 9,446,351,731, an increase from CNY 9,213,956,461 at the end of Q3 2022[31] - The net cash flow from operating activities for the first three quarters of 2023 was CNY 10,316,787,860, significantly higher than CNY 7,709,650,548 in the same period of 2022, indicating improved operational efficiency[30] - The company’s total liabilities increased to ¥19,770,878,845.60 from ¥17,763,654,011.21, indicating a rise of about 11.3%[27] - The company’s total liabilities as of September 30, 2023, were reported to be lower than the previous year, indicating improved financial health[36] Future Outlook - In Q4 2023, the company expects revenue from non-specific commercial production projects to exceed RMB 10 billion for the first time, with a projected growth of 29-34% excluding specific projects[18] - The overall revenue for 2023 is anticipated to surpass RMB 40 billion, with a growth of 25-26% when excluding specific commercial production projects[18] - The adjusted non-IFRS gross margin for 2023 is raised to approximately 41.7-42.1%, an increase of about 0.5 percentage points[18] - The adjusted net profit attributable to the parent company is expected to exceed RMB 10 billion for the first time in 2023[18] - Free cash flow under IFRS for 2023 is projected to be between RMB 4.5-5 billion, over 17 times that of the same period last year[18] - The company has adjusted its revenue growth forecast for 2023 from 5-7% to 2-3% due to lower-than-expected demand in early-stage drug development[18] Shareholder Information - The total number of ordinary shareholders as of September 30, 2023, is 202,845[20] - The largest shareholder, HKSCC NOMINEES LIMITED, holds 402,500,362 shares, representing 13.56% of the total[20] - The company’s total equity attributable to shareholders increased to CNY 51,586,653 thousand from CNY 46,589,953 thousand, reflecting a growth of about 10.5%[38] Research and Development - The company added 926 new molecules to its D&M pipeline, surpassing a total of 3,000 molecules, including 58 commercial projects and 61 clinical phase III projects[14] - The company plans to continue focusing on R&D and market expansion strategies to drive future growth, although specific figures were not disclosed in the report[32]

Financial Performance - The company's operating revenue for Q3 2023 was approximately RMB 10.67 billion, representing a year-on-year increase of 0.30%[7] - The net profit attributable to shareholders for the same period was approximately RMB 2.76 billion, reflecting a year-on-year increase of 0.77%[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately RMB 2.95 billion, with a significant year-on-year increase of 23.76%[7] - The cash flow from operating activities for the year-to-date period reached approximately RMB 10.32 billion, showing a substantial increase of 33.82% compared to the previous year[7] - The basic earnings per share for Q3 2023 was RMB 0.94, an increase of 1.08% year-on-year[7] - The diluted earnings per share for the same period was also RMB 0.94, reflecting a significant increase of 16.05% year-on-year[7] - The company achieved operating revenue of RMB 29.54 billion in the first three quarters of 2023, representing a year-on-year growth of 4.0%[12] - Total operating revenue for the first three quarters of 2023 reached RMB 29.54 billion, an increase of 4.03% compared to RMB 28.39 billion in the same period of 2022[27] - Net profit for the first three quarters of 2023 was RMB 8.15 billion, representing a growth of 9.43% from RMB 7.45 billion in the same period of 2022[28] - The company reported a total profit of RMB 9.78 billion, an increase of 10.98% compared to RMB 8.82 billion in the same period of 2022[27] - The total comprehensive income for the first three quarters was RMB 7.60 billion, an increase of 13.63% from RMB 6.69 billion in the same period of 2022[30] Revenue Sources - Revenue from American clients reached RMB 19.4 billion, with a year-on-year growth of 36% after excluding COVID-19 commercialization projects[10] - Revenue from the top 20 global pharmaceutical companies reached RMB 11.82 billion, with a strong year-on-year growth of 43% after excluding COVID-19 projects[10] - The company’s revenue from existing clients accounted for nearly 99%, totaling RMB 29.12 billion, with a year-on-year growth of 26% after excluding COVID-19 projects[10] - Revenue from the testing business was RMB 4.85 billion, reflecting a year-on-year increase of 16.2%[14] - WuXi Biology achieved revenue of RMB 1.89 billion, a year-on-year increase of 6.5%, with an adjusted gross margin of 42.8%, up 1.6 percentage points year-on-year[15] - WuXi ATU's cell and gene therapy CTDMO business generated revenue of RMB 1.03 billion, an increase of 11.6% year-on-year, with an adjusted gross margin of -6.1%[16] - The new molecular biology-related revenue in the biology segment grew strongly by 35% year-on-year, contributing 25.9% to the overall biology business revenue[15] Cash Flow and Assets - The cash flow from operating activities increased by 33.82% year-on-year, attributed to stable revenue collection and optimized working capital management[9] - Cash and cash equivalents reached ¥9,448,561,845.32, up from ¥7,985,741,393.85, reflecting a growth of about 18.3%[24] - Total current assets amounted to ¥29,777,189,611.66, an increase of approximately 24.0% from ¥23,997,226,540.21 on December 31, 2022[24] - Total assets as of September 30, 2023, were ¥71,759,281,237.93, compared to ¥64,690,326,746.96 at the end of 2022, indicating a growth of around 10.0%[26] - The company’s cash balance at the end of the third quarter of 2023 was ¥9,446,351,731.41, compared to ¥9,213,956,461.06 at the end of the third quarter of 2022[33] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 202,845[19] - The company paid dividends amounting to RMB 2,649,084 thousand in 2023, which is an increase of 73.4% compared to RMB 1,529,442 thousand in 2022[39] Future Outlook - The company expects significant growth in TIDES business revenue in Q4 2023, projected to exceed 60% for the full year[13] - The company anticipates that revenue from non-COVID commercial production projects in Q4 2023 will exceed RMB 10 billion for the first time[18] - Excluding COVID-related projects, the company expects Q4 revenue growth of 29-34% and a full-year revenue increase of 25-26%[18] - The adjusted gross margin for the full year 2023 is projected to be between 41.7% and 42.1%, with net profit expected to exceed RMB 10 billion for the first time[18] - The company has adjusted its 2023 revenue growth forecast from 5-7% to 2-3% due to lower-than-expected demand in early drug development stages[18] Employee Information - The company employed a total of 41,148 staff, with 12,877 holding a master's degree or above, and 1,400 holding a doctoral degree or equivalent[5] - The company continues to focus on talent retention through recruitment, training, promotion, and incentives to maintain high service standards and industry leadership[5]

证券代码：603259 证券简称：药明康德 公告编号：临 2023-065 无锡药明康德新药开发股份有限公司 第三届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 无锡药明康德新药开发股份有限公司（以下简称"本公司"或"公司"）于 2023 年 10 月 16 日及 2023 年 10 月 29 日向本公司全体董事发出会议通知及会议 材料。经全体董事一致认可，以现场结合通讯表决方式于 2023 年 10 月 30 日按 期召开第三届董事会第四次会议。本次董事会会议应出席董事 12 人，实际出席 董事 12 人。会议由董事长 Ge Li（李革）主持。本次董事会符合《中华人民共和 国公司法》和《无锡药明康德新药开发股份有限公司章程》关于召开董事会会议 的规定。 二、董事会会议审议情况 （一）审议通过《关于公司 2023 年第三季度报告的议案》 同意《无锡药明康德新药开发股份有限公司 2023 年第三季度报告》的相关 内容。 具体内容详见本公司同日于上海证券交易所网站（www.sse ...

证券代码：603259 证券简称：药明康德 公告编号：临 2023-067 无锡药明康德新药开发股份有限公司 关于终止公司 2023 年 H 股奖励信托计划及回购注销 H 股股份的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 无锡药明康德新药开发股份有限公司（以下简称"公司"）于 2023 年 5 月 31 日召开 2022 年年度股东大会审议通过了《关于审议<无锡药明康德新药开发 股份有限公司 2023 年 H 股奖励信托计划（草案）>的议案》（所通过的计划以 下简称"《2023 年 H 股奖励信托计划》"）、《关于授权董事会办理 2023 年 H 股奖励信托计划相关事宜的议案》等议案，具体内容详见公司披露的《2022 年年 度股东大会、2023 年第一次 A 股类别股东会议及 2023 年第一次 H 股类别股东 会议会议材料（更新）》及公告编号为临 2023-038 的相关股东会议决议公告。 受托人据此使用公司自有资金通过市场内交易方式购买了公司 15,467,500 股 H 股股票（以下简称"已购入 H 股奖励股票 ...

无锡药明康德新药开发股份有限公司（以下简称"本公司"）于 2023 年 5 月 31 日召开的 2022 年年度股东大会审议通过了《关于审议<无锡药明康德新药 开发股份有限公司 2023 年 H 股奖励信托计划（草案）>的议案》《关于授权董 事会办理 2023 年 H 股奖励信托计划相关事宜的议案》等议案，于同日召开的 2022 年年度股东大会、2023 年第一次 A 股类别股东会议及 2023 年第一次 H 股 类别股东会议审议通过了《关于给予董事会回购公司 A 股和/或 H 股股份一般性 授权的议案》。2023 年 10 月 30 日，本公司第三届董事会第四次会议审议通过 了《关于终止公司 2023 年 H 股奖励信托计划及回购注销 H 股股份的议案》，决 定终止实施《无锡药明康德新药开发股份有限公司 2023 年 H 股奖励信托计划》， 并拟回购注销 15,467,500 股 H 股股份，注销完成后相应减少本公司注册资本人 民 币 15,467,500 元， 具 体内 容详 见 本公 司 同日 于上 海 证券 交 易所 网 站 （www.sse.com.cn）及指定媒体披露的《关于终止公司 2023 年 ...

《关于终止公司 2023 年 H 股奖励信托计划及回购注销 H 股股份的议案》已 经公司第三届董事会第四次会议审议通过，表决程序符合有关规定。我们认为： 无锡药明康德新药开发股份有限公司独立董事 关于公司第三届董事会第四次会议审议的相关事项的独立意见 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独立董 事管理办法》《上海证券交易所股票上市规则》《无锡药明康德新药开发股份有限 公司章程》等有关规定，作为无锡药明康德新药开发股份有限公司（以下简称"公 司"）独立董事，基于独立、客观判断的原则，我们对公司第三届董事会第四次 会议审议的《关于终止公司 2023 年 H 股奖励信托计划及回购注销 H 股股份的议 案》发表独立意见如下： 综合上述，同意公司终止《2023 年 H 股奖励信托计划》及回购注销 15,467,500 股 H 股股份。 （以下无正文，为签署页） （1）由于公司业绩增长不及预期，公司管理层主动向董事会提议终止《无 锡药明康德新药开发股份有限公司 2023 年 H 股奖励信托计划（草案）》（以下简 称"《2023 年 H 股奖励信托计划》"），公司已根据《2023 年 H 股奖励信 ...

呈交日期： 2023年10月25日 | 第一章節 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | | | 於香港聯交所上市(註11) | 否 | | | | | | 證券代號 (如於香港聯交所上市) | 說明 | 普通股A股 | | | | | | | | | | 發行股份 (註6及7) | 股份數目 | 已發行股份佔 有關股份發行前的 現有已發行股份數目 百分比 | | 每股發行價 (註1及7) | | 上一個營業日 的每股收市價 (註5) | | 發行價較市值的折讓/ 溢價幅度(百分比) (註7) | | | | | | (註4、6及7) | | | | | | | | | | 於下列日期開始時的結存(註2) 2023年9月30日 | 2,566,112,205 | | | | | | | | | | 1). | 根據股份期權計劃行使期權（發行人的董事行使除 | 24,233 | 0.001 % | RMB | | 3 ...

证券代码：603259 证券简称：药明康德 公告编号：临 2023-062 无锡药明康德新药开发股份有限公司 关于认购私募基金份额的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 投资概述 2023 年 10 月 20 日，无锡药明康德新药开发股份有限公司（以下简称"本 公司"）全资子企业无锡药明康德一期投资企业（有限合伙）（以下简称"药明一 期"）与上海华平私募基金管理有限公司（以下简称"普通合伙人"或"管理人"） 及其他合伙人签署有限合伙协议（以下简称"合伙协议"），约定由药明一期认 缴华平大健康产业投资（无锡宜兴）合伙企业（有限合伙）（以下简称"投资基 金"）不超过 60,000 万元人民币的投资基金份额（以下简称"本次投资"）。截 至本公告日，药明一期尚未支付投资款，后续药明一期将以自有资金根据合伙协 议的要求履行投资款的支付义务。 本次投资不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规 定的重大资产重组。 本次投资无需提请本公司董事会及股东大会批准。 二、 投资基金的基本情况 ...

证券代码：603259 证券简称：药明康德 公告编号：临 2023-063 无锡药明康德新药开发股份有限公司 股东减持股份结果公告 一、减持股东减持前基本情况 1 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 本次减持计划实施前，无锡药明康德新药开发股份有限公司（以下简称"公 司"）实际控制人控制的股东及与实际控制人签署一致行动协议的股东（以下简 称"减持股东"）合计持有公司 A 股股份 647,696,535 股，占公司截至 2023 年 4 月 17 日总股本的 21.83%。该等股份均为公司首次公开发行 A 股股票并上市前 所取得的股份及上市后权益分派资本公积转增股本方式取得的股份，均为无限售 条件流通股。 本次减持计划的实施结果情况 前期，公司披露了减持股东减持公司 A 股股份计划，具体详见《无锡药明康 德新药开发股份有限公司股东减持股份计划公告》（公告编号：临 2023-027）。截 至目前，减持期已届满。具体情况如下： | 股东名称 | 股东身份 | 持股数量 | 持 ...

证券代码：603259 证券简称：药明康德 公告编号：临 2023-061 无锡药明康德新药开发股份有限公司 关于股权激励限制性股票回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 回购注销原因：因无锡药明康德新药开发股份有限公司（以下简称"本 公司"或"公司"）限制性股票激励计划部分激励对象已离职或实际在岗时间不 足根据本公司政策未参与 2021 年个人年度绩效考核，不符合《无锡药明康德新 药开发股份有限公司 2019 年限制性股票与股票期权激励计划》（以下简称 "《2019 年激励计划》"）所规定的解除限售条件，其已获授但尚未解锁的限制 性股票应由公司回购注销。 2019 年 9 月 20 日，公司召开 2019 年第一次临时股东大会、2019 年第二次 A 股类别股东会及 2019 年第二次 H 股类别股东会，审议通过了《关于授权董事 会办理 2019 年股权激励计划相关事宜的议案》，授权董事会办理实施与《2019 年激励计划》有关的事项，包括按照《2019 年激励计划》的规定对激励对象尚未 解除限售的限 ...